Form 4 for IMDX Insight Molecular Diagnostics Inc.
Accepted 2022-08-17 00:00:00 ET · period of report 2022-08-15 · accession 0001493152-22-023381 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-08-17 | 2022-08-15 | IMDX | John Anish M. | CFO | A - Grant | $0.00 | +150.0K | 150.0K | New | $0 |
| D | 2022-08-17 | 2022-08-15 | IMDX | John Anish M. | CFO | A - Grant | $0.00 | +100.0K | 100.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, no par value | 2022-08-15 | A | A | 150,000 | $0.00 | 150,000 | D | — | — | (F1) The Restricted Stock Units shall vest on January 1, 2024 based on the achievement of a pre-determined financial objective related to the Issuer's available cash. |
| 2 | Derivative | Option to Purchase Common Stock | 2022-08-15 | A | A | 100,000 | $0.00 | 100,000 | D | $0.97 · — to 2032-08-15 | 100,000 Common Stock | (F2) 25% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date. |